Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy EyePoint Pharmaceuticals stock in Canada | $11.72

Own EyePoint Pharmaceuticals shares in just a few minutes.

EyePoint Pharmaceuticals is a biotechnology business based in the US. EyePoint Pharmaceuticals stocks (EYPT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.01 – an increase of 6.16% over the previous week. EyePoint Pharmaceuticals employs 98 staff and has a trailing 12-month revenue of around $39.2 million.

How to buy EyePoint Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: EYPT in this case.
  5. Research EyePoint Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your EyePoint Pharmaceuticals stocks. It's that simple.

Is it a good time to buy EyePoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted EyePoint Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, EyePoint Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $11.72, which is 87.63% up on its pre-crash value of $1.45 and 1,346.91% up on the lowest point reached during the March crash when the stocks fell as low as $0.81.

If you had bought $1,000 worth of EyePoint Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $480.16 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $6,136.12.

EyePoint Pharmaceuticals stock price

Use our graph to track the performance of EYPT stocks over time.

EyePoint Pharmaceuticals stocks at a glance

Information last updated 2021-09-26.
Latest market close$11.72
52-week range$3.511 - $15.06
50-day moving average $10.3685
200-day moving average $9.6579
Wall St. target price$21.2
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.057

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

EyePoint Pharmaceuticals price performance over time

Historical closes compared with the last close of $11.72

1 week (2021-09-20) 10.46%
1 month (2021-08-27) 16.50%
3 months (2021-06-25) 23.11%
6 months (2021-03-26) 17.43%
1 year (2020-09-25) 1,979.12%
2 years (2019-09-27) 551.11%
3 years (2018-09-27) 211.70%
5 years (2016-09-27) 262.85%

EyePoint Pharmaceuticals financials

Revenue TTM USD$39.2 million
Gross profit TTM USD$11.2 million
Return on assets TTM -18.12%
Return on equity TTM -74.85%
Profit margin -106.12%
Book value $3.717
Market capitalisation USD$337.2 million

TTM: trailing 12 months

How to short and sell EyePoint Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "EYPT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.4 million EyePoint Pharmaceuticals stocks held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 2.7% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals stocks can be evaluated.

EyePoint Pharmaceuticals's "short interest ratio" (SIR)

EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals stocks currently shorted divided by the average quantity of EyePoint Pharmaceuticals stocks traded daily (recently around 131709.54587581). EyePoint Pharmaceuticals's SIR currently stands at 10.79. In other words for every 100,000 EyePoint Pharmaceuticals stocks traded daily on the market, roughly 10790 stocks are currently held short.

However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals stocks, or, against the total number of tradable EyePoint Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding stocks (for every 100,000 EyePoint Pharmaceuticals stocks in existence, roughly 50 stocks are currently held short) or 0.0833% of the tradable stocks (for every 100,000 tradable EyePoint Pharmaceuticals stocks, roughly 83 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against EyePoint Pharmaceuticals.

Find out more about how you can short EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals stock dividends

We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have EyePoint Pharmaceuticals stocks ever split?

EyePoint Pharmaceuticals stocks were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for EyePoint Pharmaceuticals stocks which in turn could have impacted EyePoint Pharmaceuticals's stock price.

EyePoint Pharmaceuticals stock price volatility

Over the last 12 months, EyePoint Pharmaceuticals's stocks have ranged in value from as little as $3.511 up to $15.06. A popular way to gauge a stock's volatility is its "beta".

EYPT.US volatility(beta: 1.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.2942. This would suggest that EyePoint Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

Go to site